Kymera Therapeutics (KYMR) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic focus and capabilities

• Built expertise in targeted protein degradation (TPD) to address previously undrugged or inadequately drugged targets, maintaining a strict target selection approach over 10 years.

• Developed strong capabilities in ligand discovery and lead optimization, enabling rapid advancement from hit finding to clinical candidates.

• Demonstrated high productivity with seven molecules advanced to the clinic, supported by a research engine aiming to deliver one new development candidate annually.

• Established partnerships with Sanofi (IRAK4, phase I) and Gilead (CDK2 molecular glue) to expand reach in immunology and oncology.

Pipeline highlights and clinical progress

• STAT6 and IRF5 are the two lead wholly owned programs, with STAT6 positioned as a highly validated, high-potential target in immunology.

• IRF5 program is completing its first healthy volunteer study, with plans to initiate a phase Ib lupus study soon after.

• STAT6 targets the IL-4/IL-13 pathway, validated by the commercial success of dupilumab, and aims to address large, underserved populations in atopic dermatitis and asthma.

• STAT6 program (KT-621) showed robust degradation, strong biomarker impact, and encouraging clinical efficacy and safety in a 22-patient atopic dermatitis study.

Market opportunity and development plans

• Atopic dermatitis represents a significant market, with 6–9 million moderate to severe patients in the U.S., but only about 400,000 on advanced systemic therapies.

• Oral therapies face adoption barriers due to safety concerns, while injectables like dupilumab have limitations related to administration and patient acceptance.

• STAT6 oral therapy aims to capture a large undertreated patient segment, offering an alternative to injectables and topicals.

• Phase IIb BROADEN2 trial in atopic dermatitis completed enrollment in June 2026, with data expected before year-end; phase IIb BREADTH trial in asthma is ongoing, with data expected by end of next year.

• Plans to initiate phase III studies in atopic dermatitis by mid-next year, with ambitions to expand into additional Type 2 inflammatory indications.